Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Newswire.ca - Tue Nov 12, 6:00AM CST

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study

Read more at newswire.ca

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).